Neuroblastoma

Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011 Oct;261(1):243-57.სრული ტექსტი  აბსტრაქტი

National Comprehensive Cancer Network. Neuroblastoma [internet publication].სრული ტექსტი

Park JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 1;35(22):2580-7.სრული ტექსტი  აბსტრაქტი

Irwin MS, Naranjo A, Zhang FF, et al. Revised neuroblastoma risk classification system: a report from the Children's Oncology Group. J Clin Oncol. 2021 Oct 10;39(29):3229-41. აბსტრაქტი

1. Brodeur G, Hogarty M, Bagatell R, et al. Neuroblastoma. In: Pizzo P, Poplack D, eds. Principles and practice of pediatric oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2016:772.

2. Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011 Oct;261(1):243-57.სრული ტექსტი  აბსტრაქტი

3. Tsubota S, Kadomatsu K. Origin and initiation mechanisms of neuroblastoma. Cell Tissue Res. 2018 May;372(2):211-21. აბსტრაქტი

4. Shimada H, Ambros IM, Dehner LP, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999 Jul 15;86(2):364-72. აბსტრაქტი

5. Pollard ZF, Greenberg MF, Bordenca M, et al. Atypical acquired pediatric Horner syndrome. Arch Ophthalmol. 2010 Jul;128(7):937-40.სრული ტექსტი  აბსტრაქტი

6. Ogita S, Tokiwa K, Takahashi T, et al. Congenital cervical neuroblastoma associated with Horner syndrome. J Pediatr Surg. 1988 Nov;23(11):991-2. აბსტრაქტი

7. Zhou J, Jin M, Su Y, et al. Clinical presentation, management, and diagnostic performance of 2021 criteria for paraneoplastic neurologic syndromes in childhood. Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200242.სრული ტექსტი  აბსტრაქტი

8. Brunklaus A, Pohl K, Zuberi SM, et al. Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child. 2012 May;97(5):461-3.სრული ტექსტი  აბსტრაქტი

9. Kaplan SJ, Holbrook CT, McDaniel HG, et al. Vasoactive intestinal peptide secreting tumors of childhood. Am J Dis Child. 1980 Jan;134(1):21-4. აბსტრაქტი

10. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103.სრული ტექსტი  აბსტრაქტი

11. Stiller CA, Parkin DM. International variations in the incidence of neuroblastoma. Int J Cancer. 1992 Oct 21;52(4):538-43. აბსტრაქტი

12. Campbell K, Siegel DA, Umaretiya PJ, et al. A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019. Pediatr Blood Cancer. 2024 Jan;71(1):e30732.სრული ტექსტი  აბსტრაქტი

13. Kamihara J, Diller LR, Foulkes WD, et al. Neuroblastoma predisposition and surveillance - an update from the 2023 AACR Childhood Cancer Predisposition Workshop. Clin Cancer Res. 2024 Aug 1;30(15):3137-43.სრული ტექსტი  აბსტრაქტი

14. Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008 Oct 16;455(7215):930-5.სრული ტექსტი  აბსტრაქტი

15. Windels ML, Cordier F, Van Dorpe J, et al. PHOX2B: a diagnostic cornerstone in neurocristopathies and neuroblastomas. J Clin Pathol. 2024 May 17;77(6):378-82. აბსტრაქტი

16. Raabe EH, Laudenslager M, Winter C, et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene. 2008 Jan 17;27(4):469-76. აბსტრაქტი

17. Barr EK, Applebaum MA. Genetic predisposition to neuroblastoma. Children (Basel). 2018 Aug 31;5(9):119.სრული ტექსტი  აბსტრაქტი

18. Kamihara J, Bourdeaut F, Foulkes WD, et al. Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res. 2017 Jul 1;23(13):e98-e106.სრული ტექსტი  აბსტრაქტი

19. Del Bufalo F, De Angelis B, Caruana I, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023 Apr 6;388(14):1284-95.სრული ტექსტი  აბსტრაქტი

20. Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma. Expert Rev Anticancer Ther. 2017 Oct;17(10):889-904. აბსტრაქტი

21. Salim A, Raitio A, Pizer B, et al. Neuroblastoma: the association of anatomical tumour site, molecular biology and patient outcomes. ANZ J Surg. 2021 May;91(5):1000-4.სრული ტექსტი  აბსტრაქტი

22. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999 May-Jun;21(3):181-9. აბსტრაქტი

23. Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. 2015;66:49-63.სრული ტექსტი  აბსტრაქტი

24. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013 Mar;45(3):279-84.სრული ტექსტი  აბსტრაქტი

25. Harding M, Deyell RJ, Blydt-Hansen T. Catecholamines in neuroblastoma: driver of hypertension, or solely a marker of disease? Cancer Rep (Hoboken). 2022 Aug;5(8):e1569.სრული ტექსტი  აბსტრაქტი

26. Barco S, Gennai I, Reggiardo G, et al. Urinary homovanillic and vanillylmandelic acid in the diagnosis of neuroblastoma: report from the Italian Cooperative Group for Neuroblastoma. Clin Biochem. 2014 Jun;47(9):848-52. აბსტრაქტი

27. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466-77. აბსტრაქტი

28. Kamihara J, Bourdeaut F, Foulkes WD, et al. Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clin Cancer Res. 2017 Jul 1;23(13):e98-e106.სრული ტექსტი  აბსტრაქტი

29. Granja C, Mota L. Paediatric neuroblastoma presenting as an asymptomatic abdominal mass: a report on the importance of a complete clinical examination with a view to a timely diagnosis and therapeutic guidance in paediatric oncology. BMJ Case Rep. 2022 May 19;15(5):e247907.სრული ტექსტი  აბსტრაქტი

30. Chu CM, Rasalkar DD, Hu YJ, et al. Clinical presentations and imaging findings of neuroblastoma beyond abdominal mass and a review of imaging algorithm. Br J Radiol. 2011 Jan;84(997):81-91.სრული ტექსტი  აბსტრაქტი

31. Raitio A, Rice MJ, Mullassery D, et al. Stage 4S Neuroblastoma: what are the outcomes? A systematic review of published studies. Eur J Pediatr Surg. 2021 Oct;31(5):385-9. აბსტრაქტი

32. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol. 2001 Jun;36(6):612-22. აბსტრაქტი

33. Rossor T, Yeh EA, Khakoo Y, et al. Diagnosis and management of opsoclonus-myoclonus-ataxia syndrome in children: an international perspective. Neurol Neuroimmunol Neuroinflamm. 2022 May;9(3):e1153.სრული ტექსტი  აბსტრაქტი

34. El-Enany G, Nagui NA, Hilal RF. Stage IV adrenal neuroblastoma with subcutaneous nodules in an infant: a case report. Int J Dermatol. 2020 Aug;59(8):e274-6. აბსტრაქტი

35. Kazanowska B, Reich A, Jelen M, et al. Chronic metastatic neuroblastoma. Pediatr Blood Cancer. 2008 Apr;50(4):898-900. აბსტრაქტი

36. National Comprehensive Cancer Network. Neuroblastoma [internet publication].სრული ტექსტი

37. Park JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 1;35(22):2580-7.სრული ტექსტი  აბსტრაქტი

38. Campagna G, Rosenfeld E, Foster J, et al. Evolving biopsy techniques for the diagnosis of neuroblastoma in children. J Pediatr Surg. 2018 Nov;53(11):2235-9. აბსტრაქტი

39. Bartolucci D, Montemurro L, Raieli S, et al. MYCN impact on high-risk neuroblastoma: from diagnosis and prognosis to targeted treatment. Cancers (Basel). 2022 Sep 12;14(18):4421.სრული ტექსტი  აბსტრაქტი

40. Agrawal A, Rangarajan V, Shah S, et al. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies. Br J Radiol. 2018 Nov;91(1091):20180103.სრული ტექსტი  აბსტრაქტი

41. Hawthorne HC Jr, Nelson JS, Witzleben CL, et al. Blanching subcutaneous nodules in neonatal neuroblastoma. J Pediatr. 1970 Aug;77(2):297-300. აბსტრაქტი

42. Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nat Rev Clin Oncol. 2022 Aug;19(8):515-33.სრული ტექსტი  აბსტრაქტი

43. Bleeker G, Tytgat GA, Adam JA, et al. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev. 2015 Sep 29;2015(9):CD009263.სრული ტექსტი  აბსტრაქტი

44. Samim A, Tytgat GAM, Bleeker G, et al. Nuclear medicine imaging in neuroblastoma: current status and new developments. J Pers Med. 2021 Apr 4;11(4):270.სრული ტექსტი  აბსტრაქტი

45. Fernandez C, Geller J, Ehrlich P, et al. Renal tumors. In: Pizzo P, Poplack D, eds. Principles and practice of pediatric oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2016:753.

46. Hawkins D, Brennan B, Bolling T, et al. Ewing sarcoma. In: Pizzo P, Poplack D, eds. Principles and practice of pediatric oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2016:855.

47. Wexler L, Skapek S, Helman L. Rhabdomyosarcoma. In: Pizzo P, Poplack D, eds. Principles and practice of pediatric oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2016:798

48. Meyers R, Trobaugh-Lotario A, Malogolowkin M, et al. Liver tumors. In: Pizzo P, Poplack D, eds. Principles and practice of pediatric oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2016:726.

49. Rabin K, Gramatges M, Margolin J, et al. Acute lymphoblastic leukemia. In: Pizzo P, Poplack D, eds. Principles and practice of pediatric oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2016:463.

50. Metzger M, Krasin M, Choi J, et al. Hodgkin lymphoma. In: Pizzo P, Poplack D, eds. Principles and practice of pediatric oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2016:568.

51. Khuri FJ, Alton DJ, Hardy BE, Cook GT, Churchill BM. Adrenal hemorrhage in neonates: report of 5 cases and review of the literature. J Urol. 1980 Nov;124(5):684-7. აბსტრაქტი

52. Vukelic D, Bozinovic D, Morovic M, et al. Opsoclonus-myoclonus syndrome in a child with neuroborreliosis. J Infect. 2000 Mar;40(2):189-91. აბსტრაქტი

53. Sheth RD, Horwitz SJ, Aronoff S, et al. Opsoclonus myoclonus syndrome secondary to Epstein-Barr virus infection. J Child Neurol. 1995 Jul;10(4):297-9. აბსტრაქტი

54. Ertekin V, Tan H. Opsoclonus-myoclonus syndrome attributable to hepatitis C infection. Pediatr Neurol. 2010 Jun;42(6):441-2. აბსტრაქტი

55. Cardesa-Salzmann TM, Mora J, García Cazorla MA, et al. Epstein-Barr virus related opsoclonus-myoclonus-ataxia does not rule out the presence of occult neuroblastic tumors. Pediatr Blood Cancer. 2006 Dec;47(7):964-7. აბსტრაქტი

56. Candler PM, Dale RC, Griffin S, et al. Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies. J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):507-12.სრული ტექსტი  აბსტრაქტი

57. Irwin MS, Naranjo A, Zhang FF, et al. Revised neuroblastoma risk classification system: a report from the Children's Oncology Group. J Clin Oncol. 2021 Oct 10;39(29):3229-41. აბსტრაქტი

58. National Cancer Institute. Neuroblastoma screening (PDQ®)–patient version. Jul 2024 [internet publication].სრული ტექსტი

59. UK National Screening Committee. Neuroblastoma: ​child screening programme. 2016 [internet publication].სრული ტექსტი

60. Sokol E, Desai AV, Applebaum MA, et al. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol. 2020 Jun 10;38(17):1906-18.სრული ტექსტი  აბსტრაქტი

61. Schleiermacher G, Mosseri V, London WB, et al. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012 Oct 9;107(8):1418-22.სრული ტექსტი  აბსტრაქტი

62. Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2005 Sep 20;23(27):6474-80.სრული ტექსტი  აბსტრაქტი

63. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005 Sep 20;23(27):6459-65.სრული ტექსტი  აბსტრაქტი

64. George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005 Sep 20;23(27):6466-73.სრული ტექსტი  აბსტრაქტი

65. Yamamoto K, Hanada R, Kikuchi A, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol. 1998 Apr;16(4):1265-9. აბსტრაქტი

66. Oue T, Inoue M, Yoneda A, et al. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study. J Pediatr Surg. 2005 Feb;40(2):359-63. აბსტრაქტი

67. Okazaki T, Kohno S, Mimaya J, et al. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment. Pediatr Surg Int. 2004 Jan;20(1):27-32. აბსტრაქტი

68. Nishihira H, Toyoda Y, Tanaka Y, et al. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution. J Clin Oncol. 2000 Aug;18(16):3012-7. აბსტრაქტი

69. Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002 Apr 4;346(14):1041-6.სრული ტექსტი  აბსტრაქტი

70. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002 Apr 4;346(14):1047-53.სრული ტექსტი  აბსტრაქტი

71. Acharya S, Jayabose S, Kogan SJ, et al. Prenatally diagnosed neuroblastoma. Cancer. 1997 Jul 15;80(2):304-10. აბსტრაქტი

72. Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1313-23.სრული ტექსტი  აბსტრაქტი

73. Strother D, van Hoff J, Rao PV, et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer. 1997 Oct;33(12):2121-5. აბსტრაქტი

74. Strother D, Shuster JJ, McWilliams N, et al. Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol. 1995 Aug;17(3):254-9. აბსტრაქტი

75. Mullassery D, Farrelly P, Losty PD. Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis. Pediatr Hematol Oncol. 2014 Nov;31(8):703-16. აბსტრაქტი

76. Yang X, Chen J, Wang N, et al. Impact of extent of resection on survival in high-risk neuroblastoma: A systematic review and meta-analysis. J Pediatr Surg. 2019 Jul;54(7):1487-94. აბსტრაქტი

77. Seemann NM, Erker C, Irwin MS, et al. Survival effect of complete surgical resection of the primary tumor in patients with metastatic, high-risk neuroblastoma in a large Canadian cohort. Pediatr Blood Cancer. 2023 Jun;70(6):e30286. აბსტრაქტი

78. Fischer J, Pohl A, Volland R, et al. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months. BMC Cancer. 2017 Aug 4;17(1):520.სრული ტექსტი  აბსტრაქტი

79. Holmes K, Pötschger U, Pearson ADJ, et al. Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1/SIOPEN study. J Clin Oncol. 2020 Sep 1;38(25):2902-15.სრული ტექსტი  აბსტრაქტი

80. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999 Oct 14;341(16):1165-73.სრული ტექსტი  აბსტრაქტი

81. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009 Mar 1;27(7):1007-13.სრული ტექსტი  აბსტრაქტი

82. Laprie A, Michon J, Hartmann O, et al. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system stage II and III neuroblastoma with MYCN amplification. Cancer. 2004 Sep 1;101(5):1081-9.სრული ტექსტი  აბსტრაქტი

83. Desai AV, Heneghan MB, Li Y, et al. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma. Bone Marrow Transplant. 2016 Sep;51(9):1204-10. აბსტრაქტი

84. Proust-Houdemont S, Pasqualini C, Blanchard P, et al. Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution. Bone Marrow Transplant. 2016 Aug;51(8):1076-81. აბსტრაქტი

85. Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019 Aug 27;322(8):746-55.სრული ტექსტი  აბსტრაქტი

86. Peinemann F, van Dalen EC, Enk H, et al. Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2019 Apr 24;4:CD012442.სრული ტექსტი  აბსტრაქტი

87. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1324-34.სრული ტექსტი  აბსტრაქტი

88. Bassiri H, Benavides A, Haber M, et al. Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. Transl Pediatr. 2015 Jul;4(3):226-38.სრული ტექსტი  აბსტრაქტი

89. Saulnier Sholler GL, Gerner EW, Bergendahl G, et al. A phase I trial of DFMO targeting polyamine addiction in patients with relapsed/refractory neuroblastoma. PLoS One. 2015 May 27;10(5):e0127246.სრული ტექსტი  აბსტრაქტი

90. Sholler GLS, Ferguson W, Bergendahl G, et al. Maintenance DFMO Increases Survival in High Risk Neuroblastoma. Sci Rep. 2018 Sep 27;8(1):14445.სრული ტექსტი  აბსტრაქტი

91. Oesterheld J, Ferguson W, Kraveka JM, et al. Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons. J Clin Oncol. 2024 Jan 1;42(1):90-102.სრული ტექსტი  აბსტრაქტი

92. Mody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017;18(7):946-57.სრული ტექსტი  აბსტრაქტი

93. Markham A. Naxitamab: First Approval. Drugs. 2021 Feb;81(2):291-96. აბსტრაქტი

94. Mora J, Chan G, Morgenstern DA, et al. 891P Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: outcomes from the first prespecified analyses of the Pivotal 201 Trial. Ann Oncol. 2022;33(S7):S956.სრული ტექსტი

95. Kushner BH, Modak S, Basu E, et al. High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) for resistant osteomedullary neuroblastoma: major responses and outpatient treatment in a phase II trial [abstract]. Pediatr Blood Cancer. 2020;67(Suppl 4):S32.სრული ტექსტი

96. Zhou MJ, Doral MY, DuBois SG, et al. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). Eur J Cancer. 2015 Nov;51(16):2465-72. აბსტრაქტი

97. Wilson JS, Gains JE, Moroz V, et al. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer. 2014 Mar;50(4):801-15. აბსტრაქტი

98. George SL, Falzone N, Chittenden S, et al. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma. Nucl Med Commun. 2016 May;37(5):466-72. აბსტრაქტი

99. Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012 Oct;256(4):573-80. აბსტრაქტი

100. Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol. 2000 Feb;18(3):477-86. აბსტრაქტი

101. Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience - a pediatric oncology group study. J Clin Oncol. 1998 Jun;16(6):2007-17. აბსტრაქტი

102. Weiss BD, Yanik G, Naranjo A, et al. A safety and feasibility trial of (131) I-MIBG in newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. Pediatr Blood Cancer. 2021 Oct;68(10):e29117. აბსტრაქტი

103. Mastrangelo S, Attinà G, Zagaria L, et al. Induction regimen in high-risk neuroblastoma: a pilot study of highly effective continuous exposure of tumor cells to radio-chemotherapy sequence for 1 month. The critical role of iodine-131-metaiodobenzylguanidine. Cancers (Basel). 2022 Oct 21;14(20):5170.სრული ტექსტი  აბსტრაქტი

104. Fischer M, Moreno L, Ziegler DS, et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol. 2021 Dec;22(12):1764-76. აბსტრაქტი

105. Goldsmith KC, Park JR, Kayser K, et al. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med. 2023 May;29(5):1092-102.სრული ტექსტი  აბსტრაქტი

106. Cole KA, Ijaz H, Surrey LF, et al. Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma. Cancer. 2023 Jul 15;129(14):2245-55.სრული ტექსტი  აბსტრაქტი

107. Corbacioglu S, Lode H, Ellinger S, et al. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2024 Jul;25(7):922-32.სრული ტექსტი  აბსტრაქტი

108. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 1;118(23):6050-6.სრული ტექსტი  აბსტრაქტი

109. ClinicalTrials.gov. 131I-burtomab radioimmunotherapy for neuroblastoma central nervous system/leptomeningeal metastases. ClinicalTrials.gov identifier: NCT03275402. Dec 2021 [internet publication].სრული ტექსტი

110. ClinicalTrials.gov. Enoblituzumab (MGA271) in children with B7-H3-expressing solid tumors. ClinicalTrials.gov identifier: NCT02982941. Feb 2022 [internet publication].სრული ტექსტი

111. ClinicalTrials.gov. Testing the combination of two immunotherapy drugs (magrolimab and dinutuximab) in patients with relapsed or refractory neuroblastoma or relapsed osteosarcoma. ClinicalTrials.gov identifier: NCT04751383. Mar 2022 [internet publication].სრული ტექსტი

112. ClinicalTrials.gov. C7R-GD2.CART cells for patients with relapsed or refractory neuroblastoma and other GD2 positive cancers (GAIL-N). ClinicalTrials.gov identifier: NCT03635632. Nov 2021 [internet publication].სრული ტექსტი

113. ClinicalTrials.gov. GD2 specific CAR and interleukin-15 expressing autologous NKT cells to treat children with neuroblastoma (GINAKIT2). ClinicalTrials.gov identifier: NCT03294954. Jan 2022 [internet publication].სრული ტექსტი

114. Moreno L, Rubie H, Varo A, et al. Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatr Blood Cancer. 2017 Jan;64(1):25-31.სრული ტექსტი  აბსტრაქტი

115. London WB, Bagatell R, Weigel BJ, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer. 2017 Dec 15;123(24):4914-23.სრული ტექსტი  აბსტრაქტი

116. Haghiri S, Fayech C, Mansouri I, et al. Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue. Bone Marrow Transplant. 2021 Aug;56(8):1984-97. აბსტრაქტი

117. Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26.სრული ტექსტი  აბსტრაქტი

118. Moreno L, Vaidya SJ, Pinkerton CR, et al. Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience. Pediatr Blood Cancer. 2013 Jul;60(7):1135-40. აბსტრაქტი

119. Landier W, Knight K, Wong FL, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales - a report from the Children's Oncology Group. J Clin Oncol. 2014 Feb 20;32(6):527-34.სრული ტექსტი  აბსტრაქტი

120. Hobbie WL, Moshang T, Carlson CA, et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer. 2008 Nov;51(5):679-83.სრული ტექსტი  აბსტრაქტი

121. Grewal S, Merchant T, Reymond R, et al. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics. 2010 Apr;125(4):e938-50.სრული ტექსტი  აბსტრაქტი

122. French AE, Irwin MS, Navarro OM, et al. Long-term hepatic outcomes in survivors of stage 4S and 4 neuroblastoma in infancy. Pediatr Blood Cancer. 2012 Feb;58(2):283-8. აბსტრაქტი

123. van Casteren NJ, van der Linden GH, Hakvoort-Cammel FG, et al. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer. 2009 Jan;52(1):108-12. აბსტრაქტი

124. Ducassou A, Gambart M, Munzer C, et al. Long-term side effects of radiotherapy for pediatric localized neuroblastoma : results from clinical trials NB90 and NB94. Strahlenther Onkol. 2015 Jul;191(7):604-12. აბსტრაქტი

125. Kelly J, Damron T, Grant W, et al. Cross-sectional study of bone mineral density in adult survivors of solid pediatric cancers. J Pediatr Hematol Oncol. 2005 May;27(5):248-53. აბსტრაქტი

126. Simon T, Niemann CA, Hero B, et al. Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Dev Med Child Neurol. 2012 Apr;54(4):347-52.სრული ტექსტი  აბსტრაქტი

127. Cohen LE, Gordon JH, Popovsky EY, et al. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. Bone Marrow Transplant. 2014 Apr;49(4):502-8.სრული ტექსტი  აბსტრაქტი

128. Applebaum MA, Henderson TO, Lee SM, et al. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015 Jan;62(1):128-33.სრული ტექსტი  აბსტრაქტი

129. Applebaum MA, Vaksman Z, Lee SM, et al. Neuroblastoma survivors are at increased risk for second malignancies: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 Feb;72:177-85. აბსტრაქტი